Substance / Medication

Angiotensin II

Overview

Active Ingredient
angiotensin II
RxNorm CUI
1999003

Indications

Angiotensin II Injection increases blood pressure in adults with septic or other distributive shock.

Labeler: Gland Pharma LimitedUpdated: 2025-06-04T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

7 trials linked to this intervention

7
Total Trials
2
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The Efficacy and Safety of Angiotensin II for Treatment of Vasoplegia in Critically Ill Patients: A Systematic Review.
Kotani Yuki, Lezzi Martina, Murru Carlotta Pia et al. · J Cardiothorac Vasc Anesth · 2025
PMID: 39800604Meta-Analysis
Analysis of clinical experience with angiotensin II: A meta-analysis and 4 AI.
Isern-de-Val Íñigo, Antón Juarros Saray, Malingre Gajino Marta et al. · Med Intensiva (Engl Ed) · 2025
PMID: 41219026Meta-Analysis
Direct Vascular Effects of Angiotensin II (A Systematic Short Review).
Nádasy György L, Balla András, Dörnyei Gabriella et al. · Int J Mol Sci · 2024
PMID: 39795971Meta-AnalysisFull text (PMC)
Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers.
Schiepatti Annalisa, Minerba Paolo, Puricelli Michele et al. · Aliment Pharmacol Ther · 2024
PMID: 38185985Meta-Analysis
ANGIOTENSIN II IN THE TREATMENT OF DISTRIBUTIVE SHOCK: A SYSTEMATIC-REVIEW AND META-ANALYSIS.
Xourgia Eleni, Exadaktylos Aristomenis K, Chalkias Athanasios et al. · Shock · 2024
PMID: 38888542Meta-Analysis
Prior Use of Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers and Clinical Outcomes of Sepsis and Septic Shock: A Systematic Review and Meta-analysis.
Shrestha Dhan Bahadur, Sedhai Yub Raj, Oli Prakash Raj et al. · J Cardiovasc Pharmacol · 2024
PMID: 37815234Meta-Analysis
The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review.
Yamaura K, Nelson A L, Nishimura H et al. · Osteoarthritis Cartilage · 2023
PMID: 36586717Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Angiotensin II (substance)
SNOMED CT
85267009
UMLS CUI
C0003009
RxNorm CUI
1999003
Labeler
Gland Pharma Limited

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

1
Conditions
1
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.